Abiraterone Acetate (CB7630)

For research use only.

Catalog No.S2246

23 publications

Abiraterone Acetate (CB7630) Chemical Structure

CAS No. 154229-18-2

Abiraterone Acetate (CB7630) is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM in a cell-free assay. Abiraterone acetate is an oral androgen biosynthesis inhibitor.

Size Price Stock Quantity  
USD 170 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Abiraterone Acetate (CB7630) has been cited by 23 publications

Purity & Quality Control

Choose Selective P450 (e.g. CYP17) Inhibitors

Biological Activity

Description Abiraterone Acetate (CB7630) is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM in a cell-free assay. Abiraterone acetate is an oral androgen biosynthesis inhibitor.
Features Abiraterone is a drug used in castration-resistant prostate cancer.
Targets
CYP17 [1]
(Cell-free assay)
72 nM
In vitro

Abiraterone shows a good complexation with the heme iron only in SM1. [1] Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. Abiraterone also blocks 3β-hydroxysteroid dehydrogenase (3βHSD), an enzyme that is absolutely required for the synthesis of biologically active androgens. Abiraterone inhibits conversion of DHEA to Δ4-androstenedione. Abiraterone inhibition of 3βHSD blocks DHT synthesis and the androgen receptor response. Abiraterone inhibits the conversion of Δ5-androstenediol to testosterone. [2] Abiraterone inhibits C17,20-lyase, with an IC50 of 5.8 nM, in rat testis microsomes. Abiraterone significantly inhibits testosterone secretion (−48%) and in turn increases LH concentration (192%). [3] Abiraterone inhibits in vitro proliferation and AR-regulated gene expression of AR-positive prostate cancer cells, which could be explained by AR antagonism in addition to inhibition of steroidogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
JM109 NVPGWmpPTnWwY4Tpc44h[XO|YYm= NUTYTllpUW6qaXLpeIlwdiCxZjDDMZRmem2rbnHsJGhqey22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hS1mSMUfBNYRmdHSjMUnIJI12fGGwdDDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBLVTFyOTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBxem:pZYP0[ZJwdmViaInkdo95gWyjdHnvckBqdiCycnXz[Y5k\SCxZjDjfZRw[2i{b33lJHA1PTBicnXkeYN1[XOnIHL5JGhRVENvVW[gcYV1cG:mLDDJR|UxKD1iMD6wNFk1KM7:TT6= Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OUK3NFMoRjJ7N{myO|A{RC:jPh?=
P450c17-LNCaP MV;GeY5kfGmxbjDhd5NigQ>? NEC4ZnBKdiC4aYTyc{BkgXSxY3jyc41mKFB2NUCgNVdCOSCrbnjpZol1cW:wIIfhd{Bie3OjeXXkJJV{cW6pIITo[UBz[XCrZDDhZ4V1cWNiYXPp[EBz\WynYYPpcoch[XO|YYmgLGFCWkFrLDD1eIltcXqrbnegbY51[WO2IGC0OVBkOTdvZYjwdoV{e2mwZzDFd4Np\XKrY3jpZUBkd2yrIH;yJHA1PTClMUetUG5E[VBiY3XscJMh[XNidHjlJIVvgnmvZTDzc5Vz[2VuIFnDOVAhRSByLkig{txONg>? M3nyb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{N{ezNFM6Lz5zMke3N|A{QTxxYU6=
V79MZh11B1 NFvrVVRHfW6ldHnvckBie3OjeR?= Ml3vTY5pcWKrdHnvckBw\iCqdX3hckBEYVBzMVKxJIV5eHKnc4Pl[EBqdiCqYX3zeIVzKFZ5OV3abFEySjFiY3XscJMtKEmFNUCgQUAyNjZyODFOwG0v NEHLeoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[3Nlg3QCd-MUi2O|I5Pjh:L3G+
V79MZh11B1 MYTGeY5kfGmxbjDhd5NigQ>? Ml;XTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDXXAyOUJzIHX4dJJme3OnZDDpckBmgHC{ZYPz[YQhcW5iVke5UXppOTGEMTDj[YxteyxiSVO1NEA:KDFwNkC4JO69VS5? M2XTVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkGxNVc1Lz5zOUKxNVE4PDxxYU6=
V79MZh NHmwOZpHfW6ldHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGN[WDFzQkGg[ZhxemW|c3XkJIlvKGijbYP0[ZIhXjd7TWroJINmdGy|LDDJR|UxKD1iMT62NUDPxE1w NIX2bmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW1NFEyQCd-MkC1OVAyOTh:L3G+
V79MZh MoPnSpVv[3Srb36gZZN{[Xl? MmmwTY5pcWKrdHnvckBw\iCqdX3hckBEYVBzMVKxJIV5eHKnc4Pl[EBqdiCqYX3zeIVzKFZ5OV3abEBk\WyuczD1d4lv\yCdMTyyMVNJZS1zMT3k[Y95gWOxcoTpZ49{fGW{b37lJIF{KHO3YoP0doF1\SxiSVO1NEA:KDFwNkGg{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3OUG0PUc,OjN6NUmxOFk9N2F-
V79MZh MkKySpVv[3Srb36gZZN{[Xl? M4rMbGlvcGmkaYTpc44hd2ZiaIXtZY4hS1mSMUHCNkBmgHC{ZYPz[YQhcW5iaHHtd5RmeiCYN{nNXogh[2WubIOsJGlEPTBiPTCxMlc2KM7:TT6= M2X5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUWwNVE5Lz5{MEW1NFEyQDxxYU6=
V79MZh MX;GeY5kfGmxbjDhd5NigQ>? MYPJcohq[mm2aX;uJI9nKGi3bXHuJGN[WDFzQkKg[ZhxemW|c3XkJIlvKGijbYP0[ZIhXjd7TWroJINmdGy|IIXzbY5oKFtzLEKtN2heNTFzLXTlc5h6[2:{dHnjc5N1\XKxbnWgZZMhe3Wkc4TyZZRmNCCLQ{WwJF0hOS55NTFOwG0v MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3OUG0PUc,OjN6NUmxOFk9N2F-
V79MZh11B2 MYHGeY5kfGmxbjDhd5NigQ>? MnfLTY5pcWKrdHnvckBw\iCqdX3hckBEYVBzMVKyJIV5eHKnc4Pl[EBqdiCqYX3zeIVzKFZ5OV3abFEySjJiY3XscJMtKEmFNUCgQUAyNjd3MTFOwG0v M2HiSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkeyPFY5Lz5zOE[3Nlg3QDxxYU6=
LNCAP MmPtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVLzWWtKPzJiaILz MnTKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOTlPBVEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMz6yPUDPxE1w MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTNzMECyOkc,Ojl|MUCwNlY9N2F-
hTERT-BJ NIGyUFlEgXSxdH;4bYNqfHliYYPzZZk> NIP2ZYw1QCCqcoO= NYHJWm4yS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hcFSHUmStRmoh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMhW1KEIHHzd4F6NCCJSUWwJF0hPC53IN88UU4> NWq2TGlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO|IxQDBpPkK5NVczODhyPD;hQi=>
PC3 MlnaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NF;LXJo4OiCqcoO= NYXuUmtHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuPVQh|ryPLh?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTNzMECyOkc,Ojl|MUCwNlY9N2F-
MGC803 NHjIOZVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NI[4PHY4OiCqcoO= NEDrd2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HR|gxOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{44OiEQvF2u NXe5dGZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNVAxOjZpPkK5N|ExODJ4PD;hQi=>
HeLa NFjRPG5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUW0PEBpenN? M1jNUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iNz65JO69VS5? M4HUUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUeyNFgxLz5{OUG3NlA5ODxxYU6=
PC3 NX;kRmZvS3m2b4TvfIlkcXS7IHHzd4F6 NFHoXW81QCCqcoO= NGG5dWVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDlwM{Kg{txONg>? M33FUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS4PFM4Lz5{NEG0PFg{PzxxYU6=
GES-1 M2\5eWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUL5XIVUPzJiaILz MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeHUz2xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzMz6xNkDPxE1w Mn3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl|MUCwNlYoRjJ7M{GwNFI3RC:jPh?=
T47D M1raUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\oO|IhcHK| Mk\DS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVYvQSEQvF2u M{XuN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkC5OVYzLz5{N{KwPVU3OjxxYU6=
MDA-MB-231 MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEThfGg4OiCqcoO= NV\3W4RJT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVkvOiEQvF2u Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{MEm1OlIoRjJ5MkC5OVYzRC:jPh?=
MCF7 M3XkUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfJUFg4OiCqcoO= NUHvXWJ[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTlwMzFOwG0v MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{MEm1OlIoRjJ5MkC5OVYzRC:jPh?=
MDA-MB-361 NHPhTWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\DZoh4PzJiaILz NFXER5BIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCyNE41KM7:TT6= NH;Fb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{KwPVU3Oid-MkeyNFk2PjJ:L3G+
T47D NGLnT|hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NWXYfng{PDhiaILz MnvXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWNEfEJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVAhRSB{NDFOwG0v NF7RUHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NlA5OCd-MkmxO|IxQDB:L3G+
WiDr Mk[4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVe5[2NmPDhiaILz M4j1U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV3nEdkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iNEKg{txONg>? NHq1U4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NlA5OCd-MkmxO|IxQDB:L3G+

... Click to View More Cell Line Experimental Data

In vivo Following intraperitoneal administration in a rodent model, abiraterone was found to have rapid deacetylation. When administered as its acetate pro-drug (CB 7630), it suppressed circulating testosterone to undetectable levels and markedly decreased the weights of androgen sensitive organs. Abiraterone is well tolerated and the mean elimination half-life of abiraterone in these studies was 27.6 h (thus supporting the use of once-daily dosing)[5]. Preclinical studies with abiraterone demonstrated reduction in androgen production downstream of CYP17 which resulted in decreased weight of the ventral prostate, testis, and seminal vesicles in mice[6].

Protocol

Kinase Assay:

[3]

- Collapse

C17,20-lyase activity assay:

Microsomes are diluted to a final protein concentration of 50 μg/mL in the reaction mixture which contains 0.25 M sucrose, 20 mM Tris-HCl (pH 7.4), 10 mM G6P and 1.2 IU/mL G6PDH. After equilibration at 37 °C for 10 minutes, the reaction is initiated by addition of βNADP to obtain a final concentration of 0.6 mM. Prior to the distribution of 600 μL of the reaction mixture in each tube, test compounds are evaporated to dryness under a stream of nitrogen and then are incubated at 37 °C for 10 minutes. After incubation with Abiraterone, 500 μL of the reaction mixture is transferred to tubes containing 1 μM of the enzyme substrate, 17OHP. After a further 10 minutes incubation, tubes are placed on ice and the reaction is stopped by addition of 0.1 ml NaOH 1N. Tubes are deep-frozen and stored at -20 °C until assayed for Δ4A levels. A Δ4A RIA is developed and automated on a microplate format in our laboratory using a specific antibody against Δ4A and instructions provided by Biogenesis. The separation of free and bound antigen is achieved with a dextran-coated charcoal suspension. After centrifugation, aliquots of the clear supernatant are counted in duplicates in a liquid scintillation counter. The Δ4A concentrations of unknown samples are determined from the standard curve. The detection limit is 0.5 ng/mL and the within and between assay coefficients of variation are 10.7 and 17.6%, respectively at an assay value of 13 ng/mL. The rate of enzymatic reaction is expressed as pmol of Δ4A formed per 10 minutes and per mg of protein. The value of maximum activity without inhibitor (control) is set at 100%. The IC50 values are calculated using non-linear analysis from the plot of enzyme activity (%) against log of inhibitor concentration.
Cell Research:

[4]

- Collapse
  • Cell lines: LNCaP and VCaP cells
  • Concentrations: 0 μM -10 μM
  • Incubation Time: 24 hours and 96 hours
  • Method:

    LNCaP and VCaP cells are seeded in 96-well plates and grown in CSS-supplemented phenol red-free or FBS-supplemented media for 7 days. Cells are treated with Abiraterone at 24 hours and 96 hours after plating and cell viability is determined on day 7 by adding CellTiter Glo and measuring luminescence.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Male NOD/SCID mice with LAPC4 cells
  • Dosages: 0.5 mmol/kg/d
  • Administration: Administered via s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO Insoluble
Water Insoluble
Ethanol ''''28 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 391.55
Formula

C26H33NO2

CAS No. 154229-18-2
Storage powder
in solvent
Synonyms N/A
Smiles CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04862091 Recruiting Drug: Abiraterone Acetate Tablets (I)|Drug: ZYTIGA® Metastatic Castration-resistant Prostate Cancer (mCRPC) Jiangsu HengRui Medicine Co. Ltd. April 23 2021 Phase 2
NCT04458311 Recruiting Drug: Abiraterone Acetate|Drug: Tildrakizumab Metastatic Castration Resistant Prostate Cancer Institute of Cancer Research United Kingdom|Sun Pharma Global FZE December 1 2020 Phase 1|Phase 2
NCT04735913 Recruiting Drug: Abiraterone acetate tablets Abiraterone Acetate|Gene Polymorphism|Pharmacokinetic|Metabolic Analysis|Plasma Concentration Zhongnan Hospital May 5 2020 Early Phase 1
NCT04268628 Completed Other: Serum and plasma samples analysis Metastatic Castration-resistant Prostate Cancer Janssen-Cilag Farmaceutica Ltda. March 19 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

P450 (e.g. CYP17) Signaling Pathway Map

P450 (e.g. CYP17) Inhibitors with Unique Features

Related P450 (e.g. CYP17) Products

Tags: buy Abiraterone Acetate (CB7630) | Abiraterone Acetate (CB7630) supplier | purchase Abiraterone Acetate (CB7630) | Abiraterone Acetate (CB7630) cost | Abiraterone Acetate (CB7630) manufacturer | order Abiraterone Acetate (CB7630) | Abiraterone Acetate (CB7630) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID